Tandem Diabetes Care Analyst Price Targets

Wall Street analyst price targets and consensus rating for Tandem Diabetes Care (TNDM).

Price Target Range — 11 Quarters

Analyst Consensus — 21 Analysts

12Buy

9Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$29Upside to Avg. PT+85.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Equal-Weight	$18
Sep 30, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$24→$20
Sep 24, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$31→$28
Aug 21, 2026	William Blair	Steven Lichtman	Initiate	Outperform	—
Aug 7, 2026	Citigroup	Joanne Wuensch	PT Raise	Neutral	$17→$21
Aug 7, 2026	RBC Capital	Kendall Au	PT Cut	Outperform	$30→$26
Jul 28, 2026	UBS	Patrick Wood	Assumes	Neutral	$22→$18
Jul 15, 2026	Mizuho	Anthony Petrone	PT Cut	Neutral	$24→$20
Jun 23, 2026	Deutsche Bank	Kieran Ryan	Initiate	Buy→Hold	$16
Jun 1, 2026	Wells Fargo	Larry Biegelsen	Upgrade	Equal-Weight→Overweight	$21→$27
May 28, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$22→$17
May 18, 2026	B of A Securities	Travis Steed	PT Cut	Neutral	$35→$25
May 12, 2026	Benchmark	Bruce Jackson	Initiate	Hold	—
May 11, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$35→$31
May 11, 2026	Barclays	Matt Miksic	PT Cut	Overweight	$56→$55
Apr 20, 2026	TD Cowen	Mathew Blackman	PT Raise	Buy	$25→$28
Apr 9, 2026	Goldman Sachs	David Roman	PT Cut	Neutral	$28→$25
Mar 19, 2026	Truist Securities	Richard Newitter	Upgrade	Hold→Buy	$27→$35
Mar 17, 2026	Piper Sandler	Matt O'Brien	Upgrade	Neutral→Overweight	$21→$33
Mar 2, 2026	Morgan Stanley	Patrick Wood	PT Raise	Equal-Weight	$23→$25

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18

Barclays analyst Christopher Pasquale initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Weight rating and announces Price Target of $18.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.

Benzinga Newsdesk

PRO
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating

William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform rating.

Benzinga Newsdesk

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.

Vandana Singh

PRO
Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $21

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target from $17 to $21.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $26

RBC Capital analyst Kendall Au maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and lowers the price target from $30 to $26.

Benzinga Newsdesk

Tandem Diabetes Care Inc

Tandem Diabetes Care Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18

PRO
Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

PRO
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

PRO
Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $21

PRO
RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $26

People Also Watch

People Also Watch

Tandem Diabetes Care Inc

Tandem Diabetes Care Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18

PROCitigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

PROWilliam Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

PROCitigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $21

PRORBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $26

People Also Watch

People Also Watch

PRO
Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18

PRO
Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20

PRO
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating

PRO
Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $21

PRO
RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $26